Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. / Rohrberg, Kristoffer Staal; Pappot, Helle; Lassen, Ulrik; Westman, Maj; Olesen, René K; Pfeiffer, Per; Ladekarl, Morten; Mau-Sørensen, Paul Morten; Christensen, Ib J; Skov, Birgit G.
In: Cancer Biology & Therapy, Vol. 11, No. 8, 04.2011, p. 732-9.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab
AU - Rohrberg, Kristoffer Staal
AU - Pappot, Helle
AU - Lassen, Ulrik
AU - Westman, Maj
AU - Olesen, René K
AU - Pfeiffer, Per
AU - Ladekarl, Morten
AU - Mau-Sørensen, Paul Morten
AU - Christensen, Ib J
AU - Skov, Birgit G
PY - 2011/4
Y1 - 2011/4
N2 - Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analysed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab. The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of patients did benefit from the therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR) by immunohistochemistry and KRAS mutation status detected by PCR as potential predictors of effect of therapy. High VEGF-A expression was correlated to longer overall survival (HR: 0.8, 95%CI: 0.7-0.9) and high VEGFR-2 expression to shorter progression free survival (HR: 1.4, 95%CI: 1.0-1.9). EGFR expression and KRAS mutation status were not correlated to response or survival. We conclude that VEGF-A and VEGFR-2 could potentially be predictive markers in patients with UGI cancers treated with erlotinib and bevacizumab.
AB - Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analysed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab. The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of patients did benefit from the therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR) by immunohistochemistry and KRAS mutation status detected by PCR as potential predictors of effect of therapy. High VEGF-A expression was correlated to longer overall survival (HR: 0.8, 95%CI: 0.7-0.9) and high VEGFR-2 expression to shorter progression free survival (HR: 1.4, 95%CI: 1.0-1.9). EGFR expression and KRAS mutation status were not correlated to response or survival. We conclude that VEGF-A and VEGFR-2 could potentially be predictive markers in patients with UGI cancers treated with erlotinib and bevacizumab.
M3 - Journal article
VL - 11
SP - 732
EP - 739
JO - Cancer Biology & Therapy
JF - Cancer Biology & Therapy
SN - 1538-4047
IS - 8
ER -
ID: 40195150